4//SEC Filing
Azoy Alexander 4
Accession 0001771961-25-000014
CIK 0001724521other
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 5:35 PM ET
Size
9.8 KB
Accession
0001771961-25-000014
Insider Transaction Report
Form 4
Azoy Alexander
Chief Accounting Officer
Transactions
- Sale
Common Stock
2025-12-16$21.88/sh−2,376$51,997→ 24,987 total - Sale
Common Stock
2025-12-17$22.16/sh−2,113$46,823→ 22,874 total - Sale
Common Stock
2025-12-18$22.25/sh−4,343$96,614→ 18,531 total
Footnotes (6)
- [F1]Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.42 to $22.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]Includes the unvested portion of the reporting person's RSU grants.
- [F4]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F5]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 6, 2025.
- [F6]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.90 to $22.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Documents
Issuer
Arcus Biosciences, Inc.
CIK 0001724521
Entity typeother
Related Parties
1- filerCIK 0001771961
Filing Metadata
- Form type
- 4
- Filed
- Dec 17, 7:00 PM ET
- Accepted
- Dec 18, 5:35 PM ET
- Size
- 9.8 KB